CXCL8 and neoplasm: Additionally, high tumor IL-8 gene expression was associated with worse OS in mRCC treated with atezolizumab monotherapy; importantly, high tumor IL-8 expression remained associated with worse OS even in T cell-infiltrated tumors in mRCC patients treated with atezolizumab (HR, 15.6; 95% CI, 3.15, 77.6; P = 0.0004), but not in the atezolizumab + bevacizumab group (HR, 0.96; 95% CI, 0.29, 3.2; P = 0.945) and sunitinib group (HR, 1.94; 95% CI, 0.67, 5.6; P = 0.225).